Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Sorrento Therapeutics Inc. is currently managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners and 4 distinct art units. This distribution indicates that each filing is being handled independently within the patent office, requiring a tailored approach for every application.
The busiest examiner for the portfolio is RAO, SAVITHA M, who is handling 1 pending office action. Since each of the distinct examiners is responsible for 1 action, the workload is distributed across the assigned staff. This lack of examiner overlap means the company must address the specific requirements of 4 different examiners across 4 separate art units to advance its pending applications. With the 4 distinct art units involved, the pending office actions are subject to the examination standards of multiple specialized groups, which may lead to varied prosecution timelines.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 1 | 60.7% | +30.2% |
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
| HAMA, JOANNE | 1 | 25.7% | +40.0% |
| CHATTIN, AMY MARIE | 1 | 73.6% | +44.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | HAMA, JOANNE | 104d overdue |
| 17830865 | PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF | CHATTIN, AMY MARIE | 26d |
| 18264973 | Administration of Resiniferatoxin For Treatment of Prostate Cancer | LADD, CAROLYN LOUISE | 75d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | HAMA, JOANNE | 104d overdue |
| 18561529 | Presurgical Perineural Administration of Resiniferatoxin For Reduction of Post-Operative Pain | RAO, SAVITHA M | 22d overdue |
| 17830865 | PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF | CHATTIN, AMY MARIE | 26d |
| 18264973 | Administration of Resiniferatoxin For Treatment of Prostate Cancer | LADD, CAROLYN LOUISE | 75d |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1622 | 1 |
| 1647 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18561529 | Presurgical Perineural Administration of Resiniferatoxin For Reduction of Post-Operative Pain | RAO, SAVITHA M | 1691 | §103 | Final Rejection | 22d overdue | Pending | Nov 16, 2023 |
| 18264973 | Administration of Resiniferatoxin For Treatment of Prostate Cancer | LADD, CAROLYN LOUISE | 1622 | §102§103 | Non-Final OA | 75d | Pending | Aug 10, 2023 |
| 18248079 | CD19-Directed Chimeric Antigen Receptor Constructs | HAMA, JOANNE | 1647 | §103§112 | Final Rejection | 104d overdue | Pending | Apr 06, 2023 |
| 17830865 | PLACENTA-DERIVED ALLOGENEIC CAR-T CELLS AND USES THEREOF | CHATTIN, AMY MARIE | 1643 | §103§112 | Final Rejection | 26d | Pending | Jun 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial